Skip to main
AORT

Artivion (AORT) Stock Forecast & Price Target

Artivion (AORT) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Artivion is a leading medical device company that provides a suite of aortic-centric solutions to cardiac and vascular surgeons. The company has two reportable segments: Medical Devices and Preservation Services. Its strong Q4 performance, including a 18.5% year-over-year revenue growth and a 29% increase in adjusted EBITDA, is a testament to its continued success and potential for growth. With a diverse product portfolio and a strong presence in North America and other global markets, Artivion is well-positioned to capitalize on the growing demand for aortic treatments worldwide.

Bears say

Artivion is expected to experience strong revenue growth and margin improvement due to its promising product portfolio, pipeline, and international expansion efforts. The company's 12-month price target of $58 is based on an EV/sales multiple of 6.0x its 2026 estimated sales, which is higher than its peers in the medical device and cardiovascular industries. Potential upside drivers include new product launches and approvals, as well as stronger than expected margin improvement and EBITDA growth.

Artivion (AORT) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Artivion and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Artivion (AORT) Forecast

Analysts have given Artivion (AORT) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Artivion (AORT) has a Strong Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $49, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $49, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Artivion (AORT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.